METADATA
last updated: 2026-03-06 by BA
file_name: XPrize FloodLAMP Submission - QS Part 2_ Results.md
file_date: 2020-09-08
title: FloodLAMP XPRIZE Qualifying Submission - QS Part 2 Results
category: various
subcategory: xprize
tags:
source_file_type: pdf
xfile_type: NA
gfile_url: NA
xfile_github_download_url: NA
pdf_gdrive_url: https://drive.google.com/file/d/1yi2ENCjoLdCUSZPqvt4yTjFfGyJOX9Ol/
pdf_github_url: https://github.com/FocusOnFoundationsNonprofit/floodlamp-archive-wip/blob/main/various/xprize/XPrize%20FloodLAMP%20Submission%20-%20QS%20Part%202_%20Results.pdf
conversion_input_file_type: pdf
conversion: msmid
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 497
words: 330
notes: 
summary_short: FloodLAMP's XPRIZE QS Part 2 (Results) submission documents the team's estimated limit of detection (1-5 copies/µL), which is based on experiments spiking ZeptoMetrix inactivated virions and Twist RNA into samples. Results are qualitative using contrived saliva samples, with no clinical validation pilots completed at time of submission.


CONTENT

***INTERNAL TITLE:*** FloodLAMP XPRIZE Qualifying Submission - QS Part 2: Results

### WHAT IS YOUR LIMIT OF DETECTION? (copies/µL)
1-5 copies/μL

### WHAT TARGETS IS YOUR LIMIT OF DETECTION BASED ON?
Our estimated limit of detection is based upon both our experiments (spiking ZeptoMetrix inactivated virions into raw samples and Twist RNA into inactivated samples) and what has been found by Rabe, Cepko, Anahtar et al in running the same assay chemistry. We have yet to do the full 20 replicates at several levels near the LOD to precisely determine it, as we have instead prioritized optimizing various aspects of the workflow (primarily handling the silica pellet prior to amplification). Our goal for the LOD is a real world raw sample level of 1e4/mL, as this gets us to 1e5/mL for a pool of 10. This is a level significantly below what has been cited as the suspected threshold for infectiousness of 1e6/mL (level "Capable to Infect Others"). A viral load of 1e5/ml is the level that the CDC seems to be recommending for new "less sensitive" tests. The viral target which we are detecting is a combination of ORF1a and N genes (using AS1e and N2 primers).

### WHAT SAMPLE TYPES ARE USED FOR YOUR LIMIT OF DETECTION?
Nasal swab, Saliva

### ARE RESULTS BASED OFF OF CLINICAL OR CONTRIVED SAMPLES?
Contrived

### WHAT SAMPLE TYPES ARE USED FOR YOUR RESULTS?
Nasal swab, Saliva

### MEDIAN POSITIVE SAMPLE CONCENTRATION (X LOD):
NA, have not yet run clinical validation pilots

### WHAT IS YOUR POSITIVE PERCENT AGREEMENT (PPA)? (%)
NA, have not yet run clinical validation pilots

### HOW MANY POSITIVE SAMPLES WERE USED?
NA, have not yet run clinical validation pilots

### WHAT IS YOUR NEGATIVE PERCENT AGREEMENT (NPA)? (%)
NA, have not yet run clinical validation pilots

### HOW MANY NEGATIVE SAMPLES WERE USED?
NA, have not yet run clinical validation pilots

### ARE YOUR RESULTS QUALITATIVE OR QUANTITATIVE?
Qualitative

### HAVE YOU CONDUCTED CROSS REACTIVITY EXPERIMENTS?
No